Last reviewed · How we verify
Foscan (TEMOPORFIN)
Foscan (Temoporfin) is a small molecule drug in the temoporfin class, used to treat neoplasm of the head and neck and squamous cell carcinoma. It is a photosensitizing agent that works by accumulating in cancer cells and reacting with light to produce a toxic compound that kills the cells. The commercial status of Foscan is not explicitly stated, but it is likely patented. Key safety considerations include its potential to cause skin and eye irritation, as well as the risk of photosensitivity reactions. Foscan has a half-life of 91.5 hours.
At a glance
| Generic name | TEMOPORFIN |
|---|---|
| Drug class | temoporfin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2001 |
Approved indications
- Neoplasm of head and neck
- Squamous cell carcinoma
Common side effects
Key clinical trials
- Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers (PHASE2)
- Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery (PHASE1)
- Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer (NA)
- Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer (PHASE1)
- Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy (PHASE2)
- Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers (PHASE2)
- Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma (PHASE2)
- Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Foscan CI brief — competitive landscape report
- Foscan updates RSS · CI watch RSS